Inogen Inc
$ 5.90
-1.99%
11 Aug - close price
- Market Cap 159,761,000 USD
- Current Price $ 5.90
- High / Low $ 6.28 / 5.86
- Stock P/E N/A
- Book Value 6.68
- EPS -0.91
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.13 %
- 52 Week High 9.13
- 52 Week Low 5.34
About
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Analyst Target Price
$12.67
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-24 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-07 |
| Reported EPS | -0.14 | -0.14 | -0.15 | -0.2 | -0.15 | -0.11 | -0.24 | -0.11 | -0.07 | -0.45 | -1.14 | -0.36 |
| Estimated EPS | -0.17 | -0.21 | -0.3424 | -0.22 | -0.22 | -0.25 | -0.49 | -0.27 | -0.39 | -0.58 | -0.62 | -0.23 |
| Surprise | 0.03 | 0.07 | 0.1924 | 0.02 | 0.07 | 0.14 | 0.25 | 0.16 | 0.32 | 0.13 | -0.52 | -0.13 |
| Surprise Percentage | 17.6471% | 33.3333% | 56.1916% | 9.0909% | 31.8182% | 56% | 51.0204% | 59.2593% | 82.0513% | 22.4138% | -83.871% | -56.5217% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INGN
2026-08-11 16:23:00
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, specifically a decline in direct sales and rentals, despite strong international growth and improved profitability. The company expects 2026 revenues to be between $355 million and $361 million, a reduction from previous estimates. Inogen is focusing on business-to-business efforts and new products like the Voxi stationary oxygen concentrator to adapt to the changing market.
2026-08-11 16:10:21
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, despite experiencing better profitability and international growth in the second quarter. The company is facing a shift in the U.S. oxygen market towards portable oxygen concentrators as initial therapy, impacting its direct-to-consumer sales, while international sales continue to grow. Inogen is expanding its business-to-business efforts and new product offerings like Voxi stationary oxygen concentrators and Aurora CPAP masks to offset these challenges.
2026-08-11 16:10:21
Inogen (INGN) trades at a significant discount compared to its industry peers, driven by improved Q2 2026 margins and strong international demand. While the company boasts a debt-free balance sheet and expanding respiratory offerings, persistent weakness in U.S. direct sales and rentals presents execution risks. The current low valuation combined with mixed operational signals suggests a cautious "hold" stance for investors.
2026-08-11 03:20:55
Inogen Inc. has launched its Aurora CPAP mask portfolio in the United States, marking its entry into the obstructive sleep apnea market. This expansion aims to leverage existing distribution channels to offer a variety of mask designs—F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows—to meet diverse patient needs. The company reports high patient satisfaction with the comfort and performance of the new masks, which are seen as a key growth catalyst in Inogen's strategy to become a broader home healthcare respiratory solutions provider.
2026-08-10 16:40:51
Inogen (INGN) reported breakeven earnings for Q2 2026, surpassing estimates, with revenues rising 3% year-over-year to $95.1 million, driven by strong international demand and new products. Despite this, the company cut its full-year 2026 revenue guidance to $355-$361 million, down from previous estimates, due to continued U.S. sales channel mix pressure and timing of international distributor purchases. The company continues to focus on expanding its respiratory care portfolio and international presence.
2026-08-09 13:39:28
Inogen, Inc. (NASDAQ:INGN) reported quarterly results last week, with revenues of US$95m matching predictions and statutory losses coming in 8.7% smaller than expected at US$0.14 per share. Following the report, analysts reconfirmed their loss per share estimates for next year but downgraded revenue estimates, forecasting slower growth than the broader industry. Despite the revenue downgrade, analysts increased their price target by 8.6% to US$12.67 per share, suggesting an improvement in the company's intrinsic value.
